Solriamfetol (Sunosi) for Excessive Daytime Sleepiness
Date: August 26, 2019
Issue #:
1579Summary:
The FDA has approved solriamfetol (Sunosi– Jazz),
a dopamine and norepinephrine reuptake inhibitor
(DNRI), to improve wakefulness in adults with excessive
daytime sleepiness (EDS) associated with narcolepsy
or obstructive sleep apnea (OSA). Pitolisant(Wakix),
an H3-receptor antagonist/inverse agonist recently
approved by the FDA for treatment of excessive
daytime sleepiness in patients with narcolepsy, will be
reviewed in a future issue.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research
More News: Drugs & Pharmacology | Narcolepsy | Obstructive Sleep Apnea | Sleep Apnea | Sleep Disorders | Sleep Medicine